WOOJUNG BIO Inc Total Liabilities
WOOJUNG BIO Inc total liabilities. Based on the latest financial reports, WOOJUNG BIO Inc (215380) has total liabilities worth ₩76.72 Billion KRW (≈ $51.99 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 215380 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of WOOJUNG BIO Inc (2016–2025)
Total liabilities of WOOJUNG BIO Inc from 2016 to 2025. This chart illustrates how WOOJUNG BIO Inc's total liabilities have evolved over time, based on quarterly financial data. Explore WOOJUNG BIO Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
WOOJUNG BIO Inc Competitors by Total Liabilities
The table below lists competitors of WOOJUNG BIO Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Filter Vision Public Company Limited
BK:FVC
|
Thailand | ฿1.32 Billion |
|
Slj Global Tbk
JK:SULI
|
Indonesia | Rp486.05 Billion |
|
Kidoz Inc
V:KIDZ
|
Canada | CA$2.19 Million |
|
Nextplat Corp
NASDAQ:NXPL
|
USA | $12.19 Million |
|
Tekom Technologies
TWO:6294
|
Taiwan | NT$891.89 Million |
|
First Graphene Ltd
F:M11
|
Germany | €3.53 Million |
|
Quickfee Ltd
AU:QFE
|
Australia | AU$68.83 Million |
|
Leviathan Gold Ltd
V:LVX
|
Canada | CA$835.69K |
Liability Composition Analysis (2016–2025)
This chart breaks down WOOJUNG BIO Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see WOOJUNG BIO Inc (215380) total assets.
Liquidity & Leverage Metrics
WOOJUNG BIO Inc Total Liabilities Ratios Explained
WOOJUNG BIO Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how WOOJUNG BIO Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for WOOJUNG BIO Inc (2016–2025)
The table below shows the annual total liabilities of WOOJUNG BIO Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩63.42 Billion ≈ $42.98 Million |
-2.92% |
| 2024-12-31 | ₩65.33 Billion ≈ $44.27 Million |
-14.45% |
| 2023-12-31 | ₩76.36 Billion ≈ $51.75 Million |
+16.98% |
| 2022-12-31 | ₩65.28 Billion ≈ $44.24 Million |
-4.95% |
| 2021-12-31 | ₩68.68 Billion ≈ $46.54 Million |
+64.36% |
| 2020-12-31 | ₩41.78 Billion ≈ $28.32 Million |
+34.91% |
| 2019-12-31 | ₩30.97 Billion ≈ $20.99 Million |
+31.15% |
| 2018-12-31 | ₩23.61 Billion ≈ $16.00 Million |
+80.62% |
| 2017-12-31 | ₩13.07 Billion ≈ $8.86 Million |
+812.36% |
| 2016-12-31 | ₩1.43 Billion ≈ $971.15K |
-- |
About WOOJUNG BIO Inc
Kolmar BioTech, Inc. engages in the various research services in South Korea. The company provides LAB CLOUD, a bio-specialized accelerator and research platform; and efficacy evaluation, clinical and histopathology, general and inhalation toxicology, behavioral test, bioanalytical, organoids, ADME, NMR analysis, SPR analysis, IND package, shared lab animal facility, breeding lab, microbial and e… Read more